BACKGROUND: People who travel to areas with high rabies endemicity and have animal contact are at increased risk for rabies exposure. We examined characteristics of international travelers queried regarding rabies vaccination during pretravel consultations at Global TravEpiNet (GTEN) practices during 2009-2010. MATERIAL AND METHODS: We performed bivariate and multivariable analyses of data collected from 18 GTEN clinics. Travel destinations were classified by strength level of rabies vaccination recommendation. RESULTS: Of 13,235 travelers, 226 (2%) reported previous rabies vaccination, and 406 (3%) received rabies vaccine at the consultation. Common travel purposes for these 406 travelers were leisure (26%), research/education (17%), and nonmedical service work (14%). Excluding the 226 who were previously vaccinated, 8070 (62%) of 13,009 travelers intended to visit one or more countries with a strong recommendation for rabies vaccination; 1675 (21%) of these 8070 intended to travel for 1 month or more. Among these 1675 travelers, 145 (9%) were vaccinated, 498 (30%) declined vaccination, 832 (50%) had itineraries that clinicians determined did not indicate vaccination, and 200 (12%) remained unvaccinated for other reasons. In both bivariate and multivariate analyses, travelers with trip durations >6 months versus 1-3 months (adjusted odds ratio [OR]=4.9 [95% confidence interval [CI] 2.1, 11.4]) and those traveling for "research/education" or to "provide medical care" (adjusted OR=5.1 [95% CI 1.9, 13.7] and 9.5 [95% CI 2.2, 40.8], respectively), compared with leisure travelers, were more likely to receive rabies vaccination. CONCLUSIONS: Few travelers at GTEN clinics received rabies vaccine, although many planned trips 1 month long or more to a strong-recommendation country. Clinicians often determined that vaccine was not indicated, and travelers often declined vaccine when it was offered. The decision to vaccinate should take into account the strength of the vaccine recommendation at the destination country, duration of stay, availability of postexposure prophylaxis, potential for exposure to animals, and likelihood of recurrent travel to high-risk destinations.
BACKGROUND:People who travel to areas with high rabies endemicity and have animal contact are at increased risk for rabies exposure. We examined characteristics of international travelers queried regarding rabies vaccination during pretravel consultations at Global TravEpiNet (GTEN) practices during 2009-2010. MATERIAL AND METHODS: We performed bivariate and multivariable analyses of data collected from 18 GTEN clinics. Travel destinations were classified by strength level of rabies vaccination recommendation. RESULTS: Of 13,235 travelers, 226 (2%) reported previous rabies vaccination, and 406 (3%) received rabies vaccine at the consultation. Common travel purposes for these 406 travelers were leisure (26%), research/education (17%), and nonmedical service work (14%). Excluding the 226 who were previously vaccinated, 8070 (62%) of 13,009 travelers intended to visit one or more countries with a strong recommendation for rabies vaccination; 1675 (21%) of these 8070 intended to travel for 1 month or more. Among these 1675 travelers, 145 (9%) were vaccinated, 498 (30%) declined vaccination, 832 (50%) had itineraries that clinicians determined did not indicate vaccination, and 200 (12%) remained unvaccinated for other reasons. In both bivariate and multivariate analyses, travelers with trip durations >6 months versus 1-3 months (adjusted odds ratio [OR]=4.9 [95% confidence interval [CI] 2.1, 11.4]) and those traveling for "research/education" or to "provide medical care" (adjusted OR=5.1 [95% CI 1.9, 13.7] and 9.5 [95% CI 2.2, 40.8], respectively), compared with leisure travelers, were more likely to receive rabies vaccination. CONCLUSIONS: Few travelers at GTEN clinics received rabies vaccine, although many planned trips 1 month long or more to a strong-recommendation country. Clinicians often determined that vaccine was not indicated, and travelers often declined vaccine when it was offered. The decision to vaccinate should take into account the strength of the vaccine recommendation at the destination country, duration of stay, availability of postexposure prophylaxis, potential for exposure to animals, and likelihood of recurrent travel to high-risk destinations.
Authors: Philippe Gautret; Marc Shaw; Pierre Gazin; Georges Soula; Jean Delmont; Philippe Parola; Marie José Soavi; Philippe Brouqui; D Elizabeth Matchett; Joseph Torresi Journal: J Travel Med Date: 2008 Jan-Feb Impact factor: 8.490
Authors: Philippe Gautret; Eli Schwartz; Marc Shaw; Georges Soula; Pierre Gazin; Jean Delmont; Philippe Parola; Marie José Soavi; Elizabeth Matchett; Graham Brown; Joseph Torresi Journal: Vaccine Date: 2007-01-03 Impact factor: 3.641
Authors: Matthias Altmann; Philippe Parola; Jean Delmont; Philippe Brouqui; Philippe Gautret Journal: J Travel Med Date: 2009 Mar-Apr Impact factor: 8.490
Authors: Lin H Chen; Mary E Wilson; Xiaohong Davis; Louis Loutan; Eli Schwartz; Jay Keystone; Devon Hale; Poh Lian Lim; Anne McCarthy; Effrossyni Gkrania-Klotsas; Patricia Schlagenhauf Journal: Emerg Infect Dis Date: 2009-11 Impact factor: 6.883
Authors: Zulkhairul Naim B Sidek Ahmad; Khairul Anwar Zarkasi; Nur Zuliani Ramli; Farrah Ilyani Che Jamaludin; Muhammad Kamil Che Hasan Journal: Int J Prev Med Date: 2022-04-05
Authors: Rhett J Stoney; Emily S Jentes; Mark J Sotir; Phyllis Kozarsky; Sowmya R Rao; Regina C LaRocque; Edward T Ryan Journal: Am J Trop Med Hyg Date: 2014-01-20 Impact factor: 2.345
Authors: Sara M Lammert; Sowmya R Rao; Emily S Jentes; Jessica K Fairley; Stefanie Erskine; Allison T Walker; Stefan H Hagmann; Mark J Sotir; Edward T Ryan; Regina C LaRocque Journal: J Travel Med Date: 2016-10-30 Impact factor: 8.490
Authors: Johnnie A Yates; Sowmya R Rao; Allison Taylor Walker; Douglas H Esposito; Mark Sotir; Regina C LaRocque; Edward T Ryan Journal: J Travel Med Date: 2019-09-02 Impact factor: 8.490